Al Sandrock

Sandrock has been Chief Executive Officer of Voyager and a Board member since 2022. Sandrock joined Voyager following a prolific career in biopharmaceutical drug development, in which he spent 23 years at Biogen where he identified and developed novel therapies for a variety of serious diseases. While at Biogen, Sandrock served in positions of increasing responsibility, culminating in his service as Executive Vice President, Research and Development. He also served as Chief Medical Officer and held a seat on the Biogen Executive Committee. Over the course of his tenure, he led the discovery and development, and regulatory approval of numerous medicines including: ADUHELM™, PLEGRIDY®, SPINRAZA®, TECFIDERA®, and TYSABRI®. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology at Massachusetts General Hospital.